Last reviewed · How we verify
Twice-daily Insulin
Insulin replaces or supplements the body's own insulin to regulate blood glucose by facilitating glucose uptake into cells and promoting glycogen synthesis.
Insulin replaces or supplements the body's own insulin to regulate blood glucose by facilitating glucose uptake into cells and promoting glycogen synthesis. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus (when oral agents are insufficient).
At a glance
| Generic name | Twice-daily Insulin |
|---|---|
| Sponsor | Hospital Universitario Dr. Jose E. Gonzalez |
| Drug class | Insulin |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin is a peptide hormone that binds to insulin receptors on cell surfaces, enabling glucose transport into muscle, fat, and liver cells. This reduces blood glucose levels and promotes anabolic metabolism. Twice-daily dosing provides basal and prandial (meal-time) coverage to maintain glycemic control throughout the day.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus (when oral agents are insufficient)
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- Safety and Feasibility of Intranasal Insulin in Patients With Spinal Cord Injury (PHASE1)
- Clinical Study to Evaluate the Possible Efficacy of Metformin in Patients With Parkinson's Disease (PHASE2)
- Sirtuin-NAD Activator in Alzheimer's Disease (PHASE1, PHASE2)
- Effect of Topical Insulin on Healing Rate of Pemphigus Lesions (PHASE2)
- Clinical Study for Dimethyl Fumarate in Preserving Islet β-Cell Function in Type 1 Diabetes Mellitus (PHASE3)
- Comparing Pump With Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism (PHASE2)
- Ceramide Containing Multivesicular Emulsion Application . . . (NA)
- Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Twice-daily Insulin CI brief — competitive landscape report
- Twice-daily Insulin updates RSS · CI watch RSS
- Hospital Universitario Dr. Jose E. Gonzalez portfolio CI